Skip to main content

ACR 2026 RheumNow CAR T Topic Compilation

Nov 16, 2026 12:18 pm
Two targets or one CAR-T in Lupus Nephritis New Rheumatic Disease after CAR-T New Treatments in Scleroderma Early Days CAR T Without Lymphodepletion CAR-T in Rheumatoid Arthritis will it stay Preliminary PK, PD, Clinical and Safety Data of NK019 in Myositis The InVivo Wave Hype or Hope

Transcription

This is an ACR twenty twenty six podcast coming to you from ACR in Orlando. Hope you enjoy it. Great rheumatologists go to great meetings like this. RoomNow live twenty twenty seven is happening January 3031 in Dallas, Texas. Join your colleagues from across the country and around the world for an interactive, engaging, and practice changing event.

Go to roomnow.live to see the full program and register today.

Hello, I'm Ehike Damoni. I'm a rheumatologist from Sao Paulo and I'm in the coverage of ACL twenty twenty six by RheumNow. Today I'm going to talk about dual target therapy, especially using CAR T therapy for lupus nephritis. First, the idea. Most CAR TIN lupus targets only CD19, which removes B cells.

But some plasma cells do not have CD19. They can survive and keep making antibodies, but a second target like BCMA can remove these cells too. So the goal is to get a deeper result. Abstract one to 15, a suit from China, test a CAR T against CD19 and BCMA. So we are talking about dual target CAR T.

It is off the shelf. It's made from a health donor. 16 patients with lupus nephritis, especially talking about the results right now, eleven of them have achieved complete renal response. Sixty nine percent of the patients at nine months. All patients were on five milligrams of prednisone or less.

CRS was mute and these patients did not have any neurotoxicity because of the treatment. So what's my read? My read is that to talking about CD19 and BCMA makes sense, two targets makes sense because some auto antibodies are productive by plasma cells so only achieving CD19 cannot bring the right result for these patients. Another point that is important is that this is an off the shelf therapy so a lot of patients can receive these without needing some stay at the hospital or time for manufacture. So I'm in HickNomaly.

I'm very glad to be with you here at RheumNow. Thank you.

David Lu here as part of RheumNow's coverage of ACR twenty twenty six. It's been a big meeting. I just wanted to bring you some of the CAR T content, something that caught my eye. It was actually a poster, from the Mayo, looking at something that's come up before, which is this idea that maybe we might get these... New rheumatic disease after CAR T.

We might get immune related adverse events after CAR T. Now, there's been a Spanish report about some of this, a while back. Obviously, we have limited numbers in terms of rheumatic or autoimmune disease CAR T. But in oncology, they've been using CAR T for some time or more years than us. And so actually, this is the opportunity to look back and see how they've gone.

Have they... Those patients developed, immune related adverse events, new rheumatic disease? So this Mayo, cohort looked at thirteen thirty five conventional, CAR T patients and looked to see what the rates were from that. So out of those, seventeen developed new onset autoimmune disease. So that's one point two seven.

The previous Spanish estimate was, just below two percent. So really in that same ballpark. So not a massive number, certainly a lot less than what you see with immune checkpoint inhibitors. And I think critically as well, when you break that down, about half of them were the non ICANS immune mediated neurotoxicity. So, but neurotoxicity, so not our classic rheumatic diseases.

When you break it down out of those thirteen thirty five, you break down to the seventeen, we saw four had sarcoid, four had a seronegative inflammatory arthritis, one each in PMR and GCA. So in amongst that, you know, causality is always really hard to determine in these situations. I think as well, even though thirteen thirty five sounds like a lot of patients when you're getting these relatively rare things, It's

very

hard to determine patterns of of of what are still small numbers. But we're really seeing something which is very different to immune checkpoint inhibitors. You know, this might be all part of, guess, expansion, cell population expansion in CAR T and that might be driving it. But fundamentally, it's a lot less phenotypic. It's a lot less structured.

It's something which is not the same and is a lot less common than immune checkpoint inhibitors. It's not the same. It's definitely a much more dispersed phenotype and I don't think it's going be as much of a problem by many orders of magnitude compared to immune checkpoint inhibitors and immune related adverse events there. So for plenty more on our CAR T content, you know where to go. Roomnow.com.

Hi. It's doctor Janet Pope. I'm here at RheumNow at ACR 2026 in beautiful Florida. Orlando is really sunny right now. I wanted to talk about scleroderma treatment, but we'll call it early days.

So there were three posters today on Sunday that I wanted to talk about. They were posters number 0222, 0223, and 0225. So on 02/22, it was looking at an uncontrolled case series of patients with pretty active diffuse systemic sclerosis, five of them in total, who were given obinutuzumab. First of all, that's off label. Secondly, they had all been on rituximab, and some of them were, either no longer responding or were getting allergic reactions to rituximab.

So they were given obinutuzumab a gram times two at baseline six months later only one gram and they were followed to a year. And what they found in general was that the patient's skin scores improved, some stayed level because some of these patients had been on rituximab for a while. There were no obvious serious adverse events of note and it looks like something that might be able to go into a trial because you got to try somewhere and then obviously having an RCT, maybe comparing with Rituximab or standard care would be kinda cool. So early days, but it kind of an interesting signal. Now the next two are about CAR T.

So on, 02/25, it was allogeneic CAR T, so it's off it's off the shelf. It's not autologous, so it's off the shelf. The patients had priming like normal with cyclophosphamide and fludarabine. And, there were reports they varied on seven to 15 patients depending on what outcomes you were looking at. But the first seven patients who had had full treatment at the lowest dose because this is a dose escalation study, they were very sick.

They had a modified Rotten skin score of 36. Some of them, but not all of them, had some interstitial lung disease or low FVC. What did they find? First of all, it looked pretty safe at the lowest dose. CRS was only two patients out of seven.

CRS might go up as the dosing of the cells that they get goes up. We'll see. But what they found was about a 16, MRSS difference from the beginning to the last assessment of these patients were assessed at anywhere. They're assessed regularly, but six to twelve months. So pretty effective.

And we can't say too much about lungs because not many people had lung disease. Whereas the next study I wanna talk about, zero two two three, this is really interesting. This is in vivo CAR T. There was only three patients. It was out of, China.

They were all pretty young, 29 year old in two of them and 36 year old in the third one. They all had high skin scores over 30 and, and ILD was present in general. What did they find with the in vivo CAR T? They found that, both skin score was improving and the ILD was improving by both function and also imaging. So pretty cool.

And they have just published in New England Journal this in vivo CAR T and lupus, so I think it's gonna go somewhere. These are early days. I think it's important to note that none of these are well controlled yet, and there's something that we need to keep our eye on. Thank you, and follow us at RheumNow, and it's Janet Pope. Thanks.

David Lu here as part of RheumNow's ACR conversions 2026 coverage. It's all happening in sunny Orlando, and we just want to kind of raise one thing that's, really caught my eye. There's a lot of CAR T development, program data that's coming out. As you'd imagine, a lot of relatively small studies are bursting through. But in amongst that, they're not all the same.

And actually, what we're seeing is a little bit of innovation and really trying to target some of the pain points that come up with CAR T. Now I guess if you think about CAR T as, really arduous and manufactured traditionally that you know you take a couple of weeks to prepare stuff you need to keep people in keep them there for some time as part of the delivery process. They need substantial lymphodepletion and that's where a lot of the risk is and then they then we get problems after that potentially as well inflammatory problems after that very broadly speaking then a lot of these things are getting chipped away at in terms of the way we do things. So one really cool thing that I saw out there was, the ALLO-three twenty nine product. And this is a CAR T that doesn't just target CD nineteen, but also CD 70.

And CD 70 is important here because actually, it's on host lymphocytes that are activated to attack donor cells. So inbuilt in this CAR T is not just what it's meant to actually do, but an active anti rejection mechanism. What does that mean? Well, what they're doing in the is they're testing it to see whether you can use it without lymphodepletion and still get the same outcome. So some patients are getting lymphodepletion but looking at the patients that aren't getting lymphodepletion these are scleroderma patients by the way and you can actually see that they're getting good clinical outcomes just the same as the cyclophosphamide patients, the fludarabine and cyclophosphamide patients as well and the lymphodepletion patients small numbers a couple of them but they seem to be doing just as well with this nineteen seventy...

CD nineteen, CD seventy targeting. And in fact, well, you can see that they get a they get a modest transient B cell drop of maybe about 25% for the first couple of months, but they don't get the really devastating lymphodepletion that we see with other therapies and we need with other therapies and the actual therapy efficacy seems to stick. Now, I mean, this is one of many abstracts out there which are doing interesting things. Another one that I saw this Alacardi off the shelf with limited lymphodepletion is doing all of this as a day procedure. You know we're at the point where things are getting pretty safe for certain types of CAR T in the first initial bit.

So why do we need to keep them in hospital? Well actually this is what they're pushing the boundaries of as well. There's a lot of other really interesting stuff like that as this whole therapeutic area evolves just in the way that things evolve for TNF inhibitors they're evolving for CAR T and it's really exciting to see that play out. So for plenty more about this CAR T journey, you know where to go. Rheumnow.com.

David Lu here covering ACR conversions 2026, and some very interesting stuff about CAR T and RA that's come out of this meeting. It's been perhaps a little less enthusiastic than what we've seen for CAR T and lupus, CAR T and Sjogren... So CAR T and scleroderma, Cartier and myositis. But nevertheless, it's understandable that manufacturers are looking at RA. They can see a really big potential market there.

They can see that there's an established pathway to therapies. There are already plenty of expensive therapies there and that there are issues and that really it'd be nice to be able to offer people options in RA. Yet at the same time they've got to compete with existing therapies and the tough balance of it. I think one thing which has we've seen, well we've seen at this meeting but also seen hyped up in general has been actually the COMPARE study which was published in Nature Medicine a couple of months ago but also was back again at this meeting. It's from Germany, not Gaelscheff but a broader group, only six patients.

But I think it gives you an idea about some of the sticking points in trying to navigate this story in rheumatoid arthritis. So firstly it's conventional CAR T and comes with all the challenges that we see there. Secondly in order to make it a valuable interpretation of this, it's highly refractory rheumatoid arthritis patients. You need to have failed at least one biologic actually multiple in practice. And so we're seeing this in the way that studies recruit as well and and I guess that makes it harder to interpret.

It's harder to apply our general conventions to this. What are what are we expecting and maybe that's actually part of the game here that and to some extent any gain is better. So anything that gives you efficacy in these tough patients is clearly promising and there's appropriate a lot of interest but you know you break through both what we've seen here and in the paper. Actually you know there's it's not necessarily going to be the cure. It's not a cure for everyone.

It's not it's not a long term panacea for everyone. We're seeing people within the year who get a response and then things bounce back again. You have to ask yourself how much of that was lymphodepletion? How much of that was something else versus actually true effect. We're seeing a lot of things creep up.

And I guess some of the other things like antibody titers, it's hard to know how to interpret. So, as we start to see bigger numbers, we're going to start to be able to ask ourselves questions about what type of patients to select. And that's going be all well and good. But I think we need to just, at this point in time for rheumatoid arthritis, set appropriate expectations. If we're going to use CAR T in this disease know that it's not going to cure it's not going to be for everyone definitely.

The people who it's for it's not necessarily going to cure them all either and we're going to have to work through all the same problems with CAR T that we are working through with lupus and scleroderma and myositis. So for plenty more about RA and plenty more about CAR T you know where to go. Roomnow.com.

Hello. My name is doctor Guillermo Valenzuela. I'm a rheumatologist and being, happy to broadcast from here from the ACR twenty twenty six. Thank you to RheumNow for giving me the chance to give you this update on the preliminary data on the NKX-nineteen in patients with myositis. This data that I will be discussing is preliminary data from the cohort of the patients in the ENTRAS-two study.

The study is a Phase one, two that uses NKX019 as the agent. NKX019 is an engineered CAR NK cell that expresses CD19 with affinity for the B cell receptor CD19. In addition, there is another modification to the construct that includes membrane bound IL-fifteen which is known to increase the killing power of the NK cell as well as the stability in the site of action. The cell is, allogeneic, it is cryopreserved and has the characteristics and the benefits of a off the shelf treatment that can be provided as an outpatient setting. In fact, 20 patients in this cohort of 20 that I will be presenting today were patients that were administered the treatment in the outpatient setting.

Another important characteristic of this cell is that it has predictable PK which has allowed us to increase the doses in incremental fashion based on the area under the curve which expresses its maximum benefit. As a matter of the study design, these patients receive initial consent. I must say also that all the patients in this clinical trial are patients with myositis with refractory disease. Patients received, as I said, consent. They underwent early conditioning chemotherapy with Fludarabine and cyclophosphamide for three consecutive days and then they receive NKX019 in three subsequent days.

The data that I presented represents three different cohorts, the one billion, two billion and four billion exploratory doses. There's also a regimen that we'll be exploring which is with four billion cells at days zero to four to maximize the area under the curve in the Cmax. The outcomes were clinical, characteristics of the patients, PKPD and also safety. Now, the results, show that, in terms of metrics, the patients achieved, five out of six patients achieved a TIS score of moderate to major in their responses. The results in terms of the muscle strength on MM8, again, out of six patients achieved major responses and the patients who had component of cutaneous manifestations, fifty percent of them showed improvement and the other half maintained their responses.

In terms of safety, the most important thing in this cohort of patients with difficult to treat myositis with an NK cell which is off the shelf and administered in the outpatient setting is that the patients do not need to stay overnight for treatment. None of the patients underwent a cytokine release syndrome or a graft versus host disease or an immune mediated cell event or I can't. No reported deaths were either in this study. So all the data that I presented certainly support the need for further exploration of NKX019 in patients with myositis. With that, would like to thank you for your attention and I hope to continue to follow us in the next presentation about safety on the same subject.

Thank you.

Hi, my name is Al Kim. I'm at ACR Convergence twenty twenty six in Orlando, Florida. And within this CAR T cell world, we're gonna be talking about in this topic discussion about in vivo CAR T cells. There were several as... Abstracts here at this conference using in vivo CAR T cell, almost all from China, but they actually are starting to generate data within humans with autoimmune diseases.

So let's talk about what they are and what the promise is and what they're actually delivering. So, you know, I think the main thing that in vivo CAR T cells allow you to get is an ability to not have to use any lymphodepletion because you are actually infecting your own T cells with a virus that allows them to be CAR T cells. So you don't need to get rid of them. And as a result, especially with autologous, you don't have to wait for a manufacturing slot and wait two, three, five weeks for the cells to come back in order to inject. So there are a couple different types of in vivo CAR T cell CAR T cell strategies right now.

One of them uses a lentivirus delivery system, and one of them uses what's called a LNP or lipid nanoparticle that usually carries messenger RNA. So with the lentivirus, this virus is going to infect the T cell, but what it does is that it delivers the CAR construct genetic information into the cell's genome and integrates it there. The integration allows for long... Lifelong expression of the CAR even in daughter cells because again it's integrated in the genome but at the same time integration concerns may occur and if it integrates in say a proto oncogene and activates it it increases your cancer risk. With lipid nanoparticles that are encode...

That have messenger RNA in them, these are designed to be transient. They come in, they float into a T cell, usually targeted by an antibody that allows them to get to the T cell. The T cell then makes the CAR construct, usually very quickly, but then since it's mRNA that's outside of the nucleus and definitely not DNA that allows the... That integrates into the genome, it's lost. And so usually the CAR T cells just live for a short period of time and the impact goes away.

There's a theoretical advantage for that too because you have a a kind of a controllable on switch. You can just try to redose every time you need to, get more CAR T cells and then just wait for the effect to wane off. So let's talk about the two, the the three different abstracts here that allow this... That, were presented that I felt like had the most information. There's one compound called JY231.

It's a lentiviral based delivery system. And, this, another one is r x I m zero zero two. This is a circular RNA lipid nanoparticle. This is targeting c seven, which is found on activated, which are found on a subset of t cells. And then another one is ARNAVY one zero one, another linear, micro, messenger RNA, but lipid nanoparticle delivery system that's targeting CD eight.

So what separates these is gonna be the onset of action. Arnavy was able to get 94% peripheral b cell depletion in the blood within six hours at their lowest dose. RXIM two, that's his IV delivery. They got CAR positive t cells in, four to six hours that were identified in the bloodstream. J y two three one, because it's a lentiviral, it takes a lot more time for it to kick into place.

So you weren't able to see any, CAR T cells until about a few days until a few days ever and peaking around day ten to day seventeen. So you're looking at hours versus days, lipid nanoparticle versus, lentivirus. The counterintuitive point though, and this is one of the takeaways I want you to go with, is that the depletion certainly outlast the payload. Arniv one hundred one was able to maintain B cell depletion up to three months in the two patients that they treated. RXIM002, IV was able to reach LLDAS endorsed in patients to month five and transient expression as a result doesn't necessarily mean transient effect.

Now two things especially from the RXIM-two that you have to be aware of despite their positive clinical data they had issues in terms of relapse. Half their patients relapsed by month six and also they had several grade three events in five out of six patients including one thrombotic microangiopathy. RNV one zero one was the quietest. They only had a grade one CRS and no ICANS, but again, they only dosed two patients. So the feasibility, think, is settled.

Whether a transient payload reaches the t... Tissue depth that autologous CAR T cells is able to reach remains unknown. And also whether redosing substitutes for depth, for depth, that's a trial we need.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×